Support PenkeInflaRx N.V. - Trending symbols
Latest News of InflaRx N.V.
| Date | Title | Read |
|---|---|---|
| 2025-05-28 07:30 | InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum | Read |
| 2025-05-22 13:30 | InflaRx to Participate in Upcoming Investor Conferences | Read |
| 2025-04-30 13:30 | InflaRx to Report First Quarter 2025 Results on May 7, 2025 | Read |
Notifications
| Type | Notification | Date |
|---|---|---|
| RSI Oversold | Oversold RSI (Relative Strength Index) | 2025-05-29 |
Trends
| 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 41 | -34 | 7 | 0 | 7 | 134 | 141 | -142 | 0 | |
| Total Other Income Expense Net | 4,007 | -940 | 3,067 | -1,360 | 1,707 | -27 | 1,680 | -3,937 | -2,258 | |
| Gross Profit | -210 | 9 | -201 | -171 | -372 | 2 | -370 | 583 | 213 | |
| Cost of Revenue | 276 | -36 | 240 | 139 | 379 | -2 | 377 | -456 | -79 | |
| Income Tax Expense | 1,234 | 0 | 1,234 | -1,228 | 5 | 0 | 5 | -5 | 0 | |
| Income before Tax | -15,647 | 2,886 | -12,761 | -650 | -13,411 | -1,411 | -14,823 | 15,315 | 493 | |
| Net Income | -15,647 | 2,886 | -12,761 | -650 | -13,411 | -1,411 | -14,823 | 15,315 | 493 | |
| Net Income from Continuing Operations | -15,647 | 2,886 | -12,761 | -650 | -13,411 | -1,411 | -14,823 | 15,315 | 493 | |
| Net Income Applicable to Common Shares | -15,647 | 2,886 | -12,761 | -650 | -13,411 | -1,411 | -14,823 | 15,315 | 493 |
Comments
How you think about this?